Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Postbiotics Plus is a microbiome therapeutics company focused on developing clinically tested, medically relevant postbiotic therapies to protect and rehabilitate the gut ecosystem. The company leverages ecosystem science to identify and formulate molecular cues created by bacteria—such as fermentation metabolites and cell wall components—that modulate immune responses and maintain microbial diversity. Their lead research focuses on mitigating antibiotic-induced microbiome injury and supporting patients undergoing intensive treatments like chemotherapy. By providing stable, non-viable alternatives to probiotics, Postbiotics Plus aims to prevent collateral damage to the gut and improve overall health outcomes in vulnerable populations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Postbiotics Plus.